BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34935978)

  • 1. Radiomics for the noninvasive prediction of the BRAF mutation status in patients with melanoma brain metastases.
    Meißner AK; Gutsche R; Galldiks N; Kocher M; Jünger ST; Eich ML; Montesinos-Rongen M; Brunn A; Deckert M; Wendl C; Dietmaier W; Goldbrunner R; Ruge MI; Mauch C; Schmidt NO; Proescholdt M; Grau S; Lohmann P
    Neuro Oncol; 2022 Aug; 24(8):1331-1340. PubMed ID: 34935978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virtual biopsy using MRI radiomics for prediction of BRAF status in melanoma brain metastasis.
    Shofty B; Artzi M; Shtrozberg S; Fanizzi C; DiMeco F; Haim O; Peleg Hason S; Ram Z; Bashat DB; Grossman R
    Sci Rep; 2020 Apr; 10(1):6623. PubMed ID: 32313236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiomics for the non-invasive prediction of PD-L1 expression in patients with brain metastases secondary to non-small cell lung cancer.
    Meißner AK; Gutsche R; Galldiks N; Kocher M; Jünger ST; Eich ML; Nogova L; Araceli T; Schmidt NO; Ruge MI; Goldbrunner R; Proescholdt M; Grau S; Lohmann P
    J Neurooncol; 2023 Jul; 163(3):597-605. PubMed ID: 37382806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiomics features based on MRI predict BRAF V600E mutation in pediatric low-grade gliomas: A non-invasive method for molecular diagnosis.
    Xu J; Lai M; Li S; Ye K; Li L; Hu Q; Ai R; Zhou J; Li J; Zhen J; Cai L; Shi C
    Clin Neurol Neurosurg; 2022 Nov; 222():107478. PubMed ID: 36244075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting the BRAF mutation with pretreatment MRI radiomics features for melanoma brain metastases receiving Gamma Knife radiosurgery.
    Kawahara D; Jensen A; Yuan J; Nagata Y; Watanabe Y
    Clin Radiol; 2023 Dec; 78(12):e934-e940. PubMed ID: 37690975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases.
    Xu Z; Lee CC; Ramesh A; Mueller AC; Schlesinger D; Cohen-Inbar O; Shih HH; Sheehan JP
    J Neurosurg; 2017 Mar; 126(3):726-734. PubMed ID: 27203149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Machine learning-based radiomics for predicting BRAF-V600E mutations in ameloblastoma.
    Li W; Li Y; Liu X; Wang L; Chen W; Qian X; Zheng X; Chen J; Liu Y; Lin L
    Front Immunol; 2023; 14():1180908. PubMed ID: 37646022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy.
    Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
    JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy.
    Hannan EJ; O'Leary DP; MacNally SP; Kay EW; Farrell MA; Morris PG; Power CP; Hill ADK
    Medicine (Baltimore); 2017 Dec; 96(48):e8404. PubMed ID: 29310328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiomics of Pediatric Low-Grade Gliomas: Toward a Pretherapeutic Differentiation of
    Wagner MW; Hainc N; Khalvati F; Namdar K; Figueiredo L; Sheng M; Laughlin S; Shroff MM; Bouffet E; Tabori U; Hawkins C; Yeom KW; Ertl-Wagner BB
    AJNR Am J Neuroradiol; 2021 Apr; 42(4):759-765. PubMed ID: 33574103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.
    Harding JJ; Catalanotti F; Munhoz RR; Cheng DT; Yaqubie A; Kelly N; McDermott GC; Kersellius R; Merghoub T; Lacouture ME; Carvajal RD; Panageas KS; Berger MF; Rosen N; Solit DB; Chapman PB
    Oncologist; 2015 Jul; 20(7):789-97. PubMed ID: 25956405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
    Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM
    Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic Biomarker-Based BRAFV600 Mutation Association and Prediction in Melanoma.
    Saadani H; van der Hiel B; Aalbersberg EA; Zavrakidis I; Haanen JBAG; Hoekstra OS; Boellaard R; Stokkel MPM
    J Nucl Med; 2019 Nov; 60(11):1545-1552. PubMed ID: 31481581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
    Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
    Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative Prediction of BRAF Mutation Status in Colorectal Cancer Using a Clinical-radiomics Model.
    Xue T; Peng H; Chen Q; Li M; Duan S; Feng F
    Acad Radiol; 2022 Sep; 29(9):1298-1307. PubMed ID: 35033450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.
    Anwar MA; Murad F; Dawson E; Abd Elmageed ZY; Tsumagari K; Kandil E
    J Surg Res; 2016 Jun; 203(2):407-15. PubMed ID: 27363650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The
    Angus L; Starmans MPA; Rajicic A; Odink AE; Jalving M; Niessen WJ; Visser JJ; Sleijfer S; Klein S; van der Veldt AAM
    J Pers Med; 2021 Apr; 11(4):. PubMed ID: 33915880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical neuropathology practice news 2-2012: BRAF V600E testing.
    Capper D; Berghoff AS; von Deimling A; Preusser M
    Clin Neuropathol; 2012; 31(2):64-6. PubMed ID: 22385786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of diffusion weighted imaging for differentiating cerebral pilocytic astrocytoma and ganglioglioma BRAF V600E-mutant from wild type.
    Ramaglia A; Tortora D; Mankad K; Lequin M; Severino M; D'Arco F; Löbel U; Benenati M; de Leng WWJ; De Marco P; Milanaccio C; Rossi A; Morana G
    Neuroradiology; 2020 Jan; 62(1):71-80. PubMed ID: 31667545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.
    Behling F; Barrantes-Freer A; Skardelly M; Nieser M; Christians A; Stockhammer F; Rohde V; Tatagiba M; Hartmann C; Stadelmann C; Schittenhelm J
    Diagn Pathol; 2016 Jun; 11(1):55. PubMed ID: 27350555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.